文献速递妇科

厄拉戈利治疗子宫肌瘤相关月经过多的疗效:一项2a期概念验证研究结果

Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
PubMed 文献 · Fertil Steril · 2017-06-01

这项概念验证、剂量递增、多队列研究纳入绝经前子宫肌瘤伴月经过多(每周期月经失血量>80 mL)女性,比较厄拉戈利单药、安慰剂及厄拉戈利联合低剂量E2/孕激素反向添加治疗3个月。厄拉戈利单药显著降低月经失血量(降幅-72%至-98%),反向添加方案降幅-80%至-85%且潮热明显减少。

要点

  • 厄拉戈利单药3个月显著降低子宫肌瘤相关月经过多,降幅-72%至-98%,300 mg BID降幅最大。
  • 反向添加方案月经失血量降幅-80%至-85%,潮热发生率18.5%-26.5%,低于单药45.5%-62.5%。
  • 总体不良事件单药组70.0%-81.3%,安慰剂组56.0%,反向添加组55.6%-70.6%。

核心结论

  • 厄拉戈利显著减少子宫肌瘤女性的月经过多。
  • 低剂量反向添加方案大幅减少潮热。

研究设计与样本

  • 概念验证、剂量递增、多队列研究,在门诊开展。
  • 纳入绝经前子宫肌瘤伴月经过多(每周期月经失血量>80 mL)女性。
  • 随机分组:厄拉戈利单药n=160,安慰剂n=50,厄拉戈利联合反向添加n=61;271例中228例完成3个月治疗。
  • 厄拉戈利单药组:100 mg每日两次、200 mg每日两次、300 mg每日两次、400 mg每日一次或600 mg每日一次(除600 mg每日一次组外均设安慰剂对照)。
  • 反向添加方案:厄拉戈利200 mg每日两次联合持续低剂量E2 0.5 mg/醋酸炔诺酮0.1 mg;或厄拉戈利300 mg每日两次联合持续E2 1 mg及周期性P 200 mg。

主要发现

  • 平均年龄41.8岁,73.8%为黑人,平均基线月经失血量267 mL。
  • 从基线至最后28天的月经失血量百分比变化:厄拉戈利单药组-72%至-98%,安慰剂组-8%至-41%,单药降幅显著大于安慰剂,300 mg每日两次降幅最大。
  • 反向添加方案平均月经失血量百分比变化为-80%至-85%。
  • 总体不良事件呈剂量非依赖(厄拉戈利单药组70.0%-81.3%),安慰剂组56.0%,反向添加组55.6%-70.6%。
  • 潮热为最常见不良事件:厄拉戈利单药组45.5%-62.5%,安慰剂组12.0%,反向添加组18.5%-26.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-dose E2/progestogen add-back therapy. DESIGN: Proof-of-concept, dose-ranging, multiple-cohort study. SETTING: Clinics. PATIENT(S): Premenopausal women with fibroids and heavy menstrual bleeding (menstrual blood loss [MBL] >80 mL per cycle). INTERVENTION(S): Three months' treatment with elagolix alone: 100 mg twice daily (BID), 200 mg BID, 300 mg BID, 400 mg once daily (QD), or 600 mg QD (all but the 600 mg QD arm were placebo controlled); or elagolix plus add-back therapy: 200 mg BID plus continuous low-dose E2 0.5 mg/norethindrone acetate 0.1 mg or elagolix 300 mg BID plus E2 1 mg continuously and cyclical P 200 mg. MAIN OUTCOME MEASURE(S): Least-squares mean percentage change in MBL; adverse events (AEs). RESULT(S): Mean age was 41.8 years; 73.8% were black; mean baseline MBL was 267 mL. Of randomized women (elagolix alone, n = 160; placebo, n = 50; elagolix with add-back therapy, n = 61), 228 of 271 completed the 3-month treatment period. The MBL percentage change from baseline to last 28 days was significantly greater with elagolix alone (range, -72% to -98%; dose-dependent reduction was highest with 300 mg BID) vs. placebo (range, -8% to -41%); mean percentage changes with add-back regimens were -80% to -85%. Overall AEs were dose independent (elagolix alone, 70.0%-81.3%) but lower with placebo (56.0%) and add-back regimens (55.6%-70.6%). Hot flush was the most common AE (elagolix alone, 45.5%-62.5%; placebo, 12.0%; add-back regimens, 18.5%-26.5%). CONCLUSION(S): Elagolix significantly reduced heavy menstrual bleeding in women with fibroids. Low-dose add-back regimens substantially reduced flushing. CLINICAL TRIAL REGISTRATION NUMBER: NCT01441635.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study. Fertil Steril. 2017. PMID: 28579415. doi:10.1016/j.fertnstert.2017.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。